A phase 1b, Open-label Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Cell Carcinoma
Objective
Primary: Determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of MEDI5752 combined with axitinib (Dose-exploration Phase) Assess safety and tolerability of MEDI5752 combined with axitinib.
Secondary: Assess the antitumor activity of MEDI5752 combined with axitinib